Takeda has partnered with US-based Prometheus Biosciences to develop and commercialise therapies for inflammatory bowel disease (IBD) in a deal worth more than US$420 M. Prometheus Biosciences is a preclinical stage company specialising in novel precision therapies and diagnostics for gastrointestinal diseases.The multitarget agreement will allow Takeda to develop and commercialise up to three drug targets identified and validated by Prometheus Biosciences.